Literature DB >> 14665505

Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.

Y C Gary Lee1, Michael H Baumann, Nick A Maskell, Grant W Waterer, Tam E Eaton, Robert J O Davies, John E Heffner, Richard W Light.   

Abstract

BACKGROUND: Pleurodesis is important in the management of malignant pleural effusions, but no consensus exists on the optimal agent or methods of pleurodesis. How pleurodesis is practiced worldwide has not been studied.
OBJECTIVES: To identify variations in the clinical practice of pleurodesis in major English-speaking countries, and to quantify the experience of pulmonologists on the effectiveness and adverse effects of different pleurodesis agents worldwide.
METHODS: Eight hundred fifty-nine pulmonologists practicing in the United States, United Kingdom, Canada, Australia, and New Zealand participated in a Web-based survey.
RESULTS: The respondents collectively perform > 8,300 pleurodesis annually. Talc was the preferred agent by most respondents (slurry, 56%; poudrage, 12%), followed by tetracycline derivatives (26%), and bleomycin (7%). Differences were seen in pleurodesis practice patterns among practitioners among and within the surveyed countries. Physicians' overall satisfaction with the available pleurodesis agents was modest (5.0 out of 8), and the reported success rate averaged only 66%. Talc (both poudrage and slurry) was perceived as significantly more effective, but was associated with significantly more pain, nausea, and fever (p < 0.05). Respiratory failure occurred more commonly with talc poudrage than with other agents (p < 0.05), and had been observed by 70% and 54% of physicians who used talc poudrage and slurry, respectively.
CONCLUSIONS: Significant variations exist in how pleurodesis is performed worldwide. Pleurodesis agents currently available are perceived as suboptimal. Talc poudrage and slurry were perceived to be more effective, but were associated with more complications, including respiratory failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14665505     DOI: 10.1378/chest.124.6.2229

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  36 in total

1.  Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report.

Authors:  Joaquim Bosch-Barrera; Jaime Espinós
Journal:  Int Arch Med       Date:  2010-05-06

2.  Comparative study of talc poudrage versus pleural abrasion for the treatment of primary spontaneous pneumothorax.

Authors:  Sergio Moreno-Merino; Miguel Congregado; Gregorio Gallardo; Rafael Jimenez-Merchan; Ana Trivino; Fernando Cozar; Marta Lopez-Porras; Jesus Loscertales
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-18

Review 3.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

4.  Effectiveness of medical thoracoscopy and thoracoscopic talc poudrage in patients with exudative pleural effusion.

Authors:  Akash Verma; Aza Taha; Sridhar Venkateswaran; Augustine Tee
Journal:  Singapore Med J       Date:  2015-05       Impact factor: 1.858

5.  Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.

Authors:  K Arapis; R Caliandro; J-B Stern; P Girard; D Debrosse; D Gossot
Journal:  Surg Endosc       Date:  2006-05-02       Impact factor: 4.584

6.  Management of pleural effusion, empyema, and lung abscess.

Authors:  Hyeon Yu
Journal:  Semin Intervent Radiol       Date:  2011-03       Impact factor: 1.513

7.  Sodium hydroxide as a sclerosing agent in patients with neoplastic pleural effusion non-candidates for VATS: results of a minimally invasive protocol.

Authors:  Micaela Raices; Matías E Czerwonko; Agustin Dietrich; Alejandro Da Lozzo; Enrique Beveraggi; David Smith
Journal:  Updates Surg       Date:  2017-08-31

8.  Quality Gaps and Comparative Effectiveness of Management Strategies for Recurrent Malignant Pleural Effusions.

Authors:  David E Ost; Jiangong Niu; Hui Zhao; Horiana B Grosu; Sharon H Giordano
Journal:  Chest       Date:  2017-08-31       Impact factor: 9.410

9.  Bleomycin in the treatment of 50 cases with malignant pleural effusion.

Authors:  Novin Nikbakhsh; Ali Pourhasan Amiri; Danial Hoseinzadeh
Journal:  Caspian J Intern Med       Date:  2011

10.  Pleurodesis with povidone-iodine, as an effective procedure in management of patients with malignant pleural effusion.

Authors:  Gholamali Godazandeh; Nasim Haji Qasemi; Mohammad Saghafi; Meisam Mortazian; Pouya Tayebi
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.